A Study to Evaluate the Efficacy and Safety of Umeclidinium Bromide/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Condition:   Pulmonary Disease, Chronic Obstructive
Interventions:   Drug: Umeclidinium bromide/Vilanterol;   Drug: Placebo ACCUHALER/DISKUS;   Drug: Fluticasone propionate/Salmeterol;   Drug: Placebo NDPI
Sponsors:   GlaxoSmithKline;   GlaxoSmithKline
Not yet recruiting – verified April 2013

View full post on ClinicalTrials.gov: asthma | received in the last 14 days